CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 526 resultados LastUpdate Última actualización 04/07/2022 [13:27:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Página1 de 22 nextPage   por página


IN VITRO METHOD FOR PREDICTING MORTALITY IN COVID-19 PATIENTS

NºPublicación: WO2022135752A1 30/06/2022

Solicitante:

FUNDACION INST DE ESTUDIOS CIENCIAS DE LA SALUD DE CASTILLA Y LEON IECSCYL IBSAL [ES]
KELVIN DAVID JOSEPH [CA]
GERENCIA REGIONAL DE SALUD DE CASTILLA Y LEON [ES]
UNIV VALLADOLID [ES]
CONSORCIO CENTRO DE INVESTIG BIOMEDICA EN RED M P CIBER [ES]
INST DINVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER IDIBAPS [ES]
UNIV BARCELONA [ES]
HOSPITAL CLINIC BARCELONA [ES]
UNIV LLEIDA [ES]
INST DE RECERCA BIOMEDICA DE LLEIDA FUNDACIO DR PIFARRE [ES]

EP_4019974_A1

Resumen de: WO2022135752A1

The present invention refers to the in vitro use of a Coronavirus antigen, measured in plasma, serum or blood samples obtained from the patient, for the prognosis and/or for predicting the mortality risk of patients suffering from Coronavirus infection, for predicting the response of patients suffering from Coronavirus infection to an antiviral therapy or for selecting patients suffering from Coronavirus infection for receiving an antiviral therapy.

traducir

A SYSTEM FOR FAST DIAGNOSIS AND IDENTIFICATION OF DISEASES CAUSED BY VIRUSES

NºPublicación: WO2022139769A1 30/06/2022

Solicitante:

ATATUERK UENIVERSITESI BILIMSEL ARASTIRMA PROJELERI BIRIMI [TR]

TR_202021713_A2

Resumen de: WO2022139769A1

The invention relates to a system providing fast diagnosis and identification of diseases caused by viruses particularly Covid-19. The system provides conduct of both virus and antibody tests by suggested sensor that enables conduct of measurement in a shorter time with better accuracy rate, comprises a sensor located in cladding with mid-part of second fibre optic cable stripped between mono-chromator and spectrometer and having nano-islets and nano-particles located therein and thus forming localised surface plasmons, a spectrometer identifying presence and quantity of RNA or antibody without change in shifting and absorption in wavelength of spectrum by conducting transmission spectrum measurements of virus RNA or antibody before and after attachment to surface, a computer improving accuracy, selectivity and detection of sensor by eliminating bias, deviation error, accuracy loss and calibration error and removing attributions from sensor response curves by applying deep learning algorithms to data obtained from sensor.

traducir

APTAMERS AND USE OF THE APTAMERS IN THE DIAGNOSIS AND TREATMENT OF A SARS-COV-2 INFECTION

NºPublicación: WO2022136600A1 30/06/2022

Solicitante:

UNIV BONN RHEINISCHE FRIEDRICH WILHELMS [DE]

EP_4019637_PA

Resumen de: WO2022136600A1

The present invention relates to an aptamer not binding to the receptor-binding domain of the SARS-CoV-2 spike glycoprotein nor inhibiting the interaction of the receptor-binding domain (RED) of spike glycoprotein with angiotensin-converting enzyme II (ACE2) and/or comprising or consisting of a nucleotide sequence SEQ ID NO: 1, a composition comprising the aptamer, and the use of the aptamer in the detection of SARS-CoV-2 or diagnosis or treatment of a SARS-CoV-2 infection.

traducir

METHOD FOR DETERMINING ACTIVE SARS-COV-2 INFECTIONS

NºPublicación: WO2022136651A1 30/06/2022

Solicitante:

CEINGE BIOTECNOLOGIE AVANZATE S C A R L [IT]
CAPOLUONGO ETTORE DOMENICO [IT]
FERRUCCI VERONICA [IT]
ZOLLO MASSIMO [IT]

Resumen de: WO2022136651A1

Method for early determination of an active SARS-CoV2 infection, based on identification of subgenomic regions of the virus, and kits specifically designed for performing it.

traducir

DEVELOPMENT OF AN INNOVATIVE INHALATION FORMULATION OF NAFAMOSTAT MESYLATE FOR THE MANAGEMENT OF COVID-19

NºPublicación: WO2022139764A2 30/06/2022

Solicitante:

EGE UENIVERSITESI [TR]
MEFAR ILAC SAN A S [TR]

Resumen de: WO2022139764A2

COVID-19 is a rapidly mutating respiratory virus with a high transmission rate that maintains the current pandemic rate for most regions of the world. The pandemic is slowing down, but it cannot be completely eliminated even in developed societies such as Israel, America and Canada, which have successfully vaccinated their communities with more than 50 percent double dose vaccinations according to WHO data. It is observed, especially in countries like Israel where strict social distancing measures are relaxed, that vaccines cannot prevent the spread of more infectious new variant viruses, and the pandemic rate peaks again. Prophylactic measures which will prevent clinical progression to severe complications before the occurrence of the disease, or in infected individuals, should be the primary research area in the fight against this respiratory virus. The present invention is related to the development of innovative inhalation formulations and preparation methods intended to be used in the prophylaxis of COVID-19-related mortality from a broad-spectrum serine protease inhibitor NM, which has a potent anti -viral and anti-inflammatory potential.

traducir

COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-COV-2 INFECTION

NºPublicación: WO2022139539A1 30/06/2022

Solicitante:

UNIV AJOU IND ACADEMIC COOP FOUND [KR]

Resumen de: WO2022139539A1

The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).

traducir

AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY AND/OR PREVENTION OF SARS-COV-2-RELATED INFECTION

NºPublicación: WO2022139631A1 30/06/2022

Solicitante:

BIOCAD JOINT STOCK CO [RU]

RU_2760301_PA

Resumen de: WO2022139631A1

The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated codon-optimized nucleic acid encoding an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to an expression cassette and a vector based thereon, as well as to an AAV5 (adeno-associated virus serotype 5)-based recombinant virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.

traducir

METHODS, DEVICES AND SYSTEMS FOR DETECTION OF BIOMARKERS

NºPublicación: WO2022140379A1 30/06/2022

Solicitante:

MIG USA LLC [US]

Resumen de: WO2022140379A1

Disclosed are methods, systems and devices for detection of biomarkers. In certain embodiments, the methods and/or devices and/or systems may be used for the detection of biomarkers characteristic of disease. For example, disclosed are methods, systems and devices that may be used to detect and distinguish a biomarker profile indicative of the presence of COVID-19 as either an active infection, or a subject in remission, or a subject who has not been exposed to the virus.

traducir

SARS-COV-2 PACKAGED RNA REFERENCE MATERIAL FOR COVID-19 VIRUS DIAGNOSIS, PREPARATION METHOD THEREFOR, AND USE THEREOF

NºPublicación: WO2022139270A1 30/06/2022

Solicitante:

KOREA RES INST STANDARDS & SCI [KR]

KR_102283733_B1

Resumen de: WO2022139270A1

The present invention relates to a SARS-CoV-2 packaged RNA reference material for COVID-19 virus diagnosis and a preparation method therefor. In addition, the present invention relates to a method for providing information about whether there is COVID-19 infection, by using the SARS-CoV-2 packaged RNA reference material. The SARS-CoV-2 packaged RNA reference material, the preparation method therefor, and the method for providing information about whether there is COVID-19 infection, by using the SARS-CoV-2 packaged RNA reference material can find a wide spectrum of applications in the COVID-19 diagnosis field. Moreover, being identified to have a between-bottle homogeneity of k=95% and exhibit long-term storage and stability by itself, the COVID-19 virus reference material enjoys the advantage of reducing false-positive determination and improving reliability.

traducir

COATING AGENT BASED ON A COPPER-NANOPARTICLE BIOHYBRID AND USE THEREOF AS A BIOCIDAL AGENT

NºPublicación: WO2022136716A1 30/06/2022

Solicitante:

CONSEJO SUPERIOR INVESTIGACION [ES]
UNIV ZARAGOZA [ES]
FUNDACION AGENCIA ARAGONESA PARA LA INVESTIG Y EL DESARROLLO ARAID [ES]
FUNDACION INSTITUTO DE INVESTIG SANITARIA ARAGON IIS ARAGON [ES]
NSTITUTO ARAGONES DE CIENCIAS DE LA SALUD IACS [ES]

Resumen de: WO2022136716A1

The present invention relates to: a hybrid material comprising a protein matrix and nanoparticles (NPs) of a type of Cu; a preparation method thereof; and the uses thereof. The material of the invention displays activity that inhibits SARS-CoV-2 proteins, which makes it usable as a biocidal agent and as an agent for coating and disinfecting materials selected from metal, paper, textiles and approved surgical face masks.

traducir

METHOD FOR SIMULTANEOUSLY INDUCING IMMUNE RESPONSE AGAINST MULTIPLE VIRUSES

NºPublicación: WO2022135563A1 30/06/2022

Solicitante:

SHANGHAI PUBLIC HEALTH CLINICAL CT [CN]

CN_114213548_A

Resumen de: WO2022135563A1

Provided is a method for simultaneously inducing an immune response against multiple viruses (such as influenza viruses and novel coronavirus). Provided is an immunogenic peptide including: (a) an immunogenic stem including an HA2 region of influenza virus hemagglutinin HA; (b) an immunogenic crown including a viral membrane protein or an immunogenic fragment thereof; and (c) optionally, other portions fused to the above-mentioned portions, wherein the virus from which the viral membrane protein is derived is different from the virus from which the HA2 region in (a) is derived.

traducir

NOVEL CORONAVIRUS RECOMBINANT PROTEIN SUBUNIT VACCINE

NºPublicación: WO2022134487A1 30/06/2022

Solicitante:

ZHEJIANG VBIOSCI INC [CN]
BEIJING VBIOSCI INC [CN]

CN_112552413_A

Resumen de: WO2022134487A1

A fusion protein of a polypeptide and a Helicobacter pylori ferritin, and a subunit vaccine for preventing novel coronavirus (SARS-CoV-2) infection prepared by using the fusion protein. The polypeptide comprises one or more S1 proteins or fragments thereof (SS0, SS1, SS2, or SS3 protein, or a mutant fragment SS1t of the SS1 protein), and the amino acid sequences thereof are derived from the sequences of the novel coronavirus S protein and are optimized. The polypeptide or fragment can be fused with the codon-optimized Helicobacter pylori ferritin by means of a linker to form a fusion protein to be expressed. The fusion protein has the advantage of being easy to purify while having a high expression level in CHO cells, and can produce a high-titer neutralizing antibody against novel coronavirus (SARS-CoV-2) after immunizing an animal, and can cover various virus strains of novel coronavirus comprising mutant strains.

traducir

USE OF COMPOUND CAPABLE OF INHIBITING INTERACTION OF CORONAVIRUS SPIKE PROTEIN WITH ACE2

NºPublicación: WO2022134733A1 30/06/2022

Solicitante:

UNIV CHINA PHARMA [CN]

CN_112245428_A

Resumen de: WO2022134733A1

Provided are a use of a compound capable of inhibiting the interaction of coronavirus Spike protein with ACE2, and a use of the compound in the preparation of a drug for treating and/or preventing SARS-CoV-2 infection. The compound can not only inhibit the interaction between coronavirus Spike protein and ACE2 protein, with IC50<1 μM, but also promote the dissociation of Spike-ACE2 complex. In addition, at the cellular level, the compound can effectively inhibit the invasion of pseudovirus of SARS-CoV-2, with IC50<2 μM. The compound can specifically bind to an RBD region of Spike protein, with KD<6 μM, which shows that the compound has a very positive effect on the preparation of medicaments for the treatment and/or prevention of coronavirus infection.

traducir

METHOD FOR PREDICTING NOVEL CORONAVIRUS NEUTRALIZING ANTIBODY TITERS AND KIT THEREFOR

NºPublicación: WO2022134241A1 30/06/2022

Solicitante:

HANGZHOU BAOLIN BIOTECHNOLOGY CO LTD [CN]

Resumen de: WO2022134241A1

Provided are a method for predicting novel coronavirus neutralizing antibody titers and a kit therefor, which belong to the technical field of neutralizing antibody titer prediction. The method for predicting the novel coronavirus neutralizing antibody titers is as follows: first, a biological sample to be tested is provided, and then an expression level of novel coronavirus-specific protein in a serum sample after binding to affinity antibodies is detected; and then the detection result is associated with neutralizing antibody titers so as to predict the neutralizing antibody titers of the novel coronavirus in the biological sample. The method above may well predict the neutralizing antibody result of the novel coronavirus merely by means of serum detection. Compared to existing plaque reduction neutralization tests and pseudovirus based neutralization assay, the present method has the advantages of a simple operation, a fast detection speed, a short detection period, and a safe detection environment, and may be used as an evaluation index for the second recurrence of novel coronavirus vaccination or infection.

traducir

COMPOSITIONS AND USES THEREOF FOR TREATING OR PREVENTING VIRAL INFECTIONS

NºPublicación: WO2022137241A1 30/06/2022

Solicitante:

GILVERDI HEALTH AND BEAUTY LTD [IL]

Resumen de: WO2022137241A1

The present invention relates to compositions comprising one or more plant- or fungus-derived compounds and their use for treating or preventing viral respiratory infections (VRIs), such as COVID-19.

traducir

HYALURONAN IS A DRIVER OF COVID-19 SEVERITY

NºPublicación: WO2022140622A1 30/06/2022

Solicitante:

UNIV VIRGINIA PATENT FOUNDATION [US]
UNIV MANCHESTER [GB]

Resumen de: WO2022140622A1

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.

traducir

USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

NºPublicación: WO2022140781A1 30/06/2022

Solicitante:

ANN AND ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO [US]

Resumen de: WO2022140781A1

Disclosed herein are methods for diagnosing and treating sepsis, acute respiratory distress syndrome (ARDS), and severe COVID-19 and associated ARDS, and also for treating elderly patients with ARDS induced by sepsis, pneumonia, and COVID-19. The disclosed methods utilize stromal cell-derived factor 1 (SDF1, also known as CXCL12) and the expression level thereof as a biomarker for diagnosing or treating sepsis, ARDS and severe and critical COVID-19.

traducir

IMMUNE-REGULATORY LI-KEY PEPTIDE VACCINES FOR PROPHYLAXIS AND LONG-TERM PROTECTION AGAINST SARS-COV-2 INFECTION AND COVID-19 DISEASE

NºPublicación: WO2022140706A1 30/06/2022

Solicitante:

PURCELL RICHARD D [US]
TERRELL JASON B [US]
VON HOFE ERIC H [US]

Resumen de: WO2022140706A1

The disclosure details methods for producing peptide-based vaccines for immunizing mammalian subjects against the SARS Coronavirus SARS-CoV-2, and additionally describes peptide vaccines and methods for immunizing mammalian subjects, including humans, to elicit a protective immune response against SARS-CoV-2 and to prevent or reduce the severity of COVID- 19 disease. Additionally, the disclosure provides methods and compositions for making and using li-Key peptide fusions with SARS-CoV-2 antigenic peptides to make immunogenic Ii-Key-SARS-CoV-2 peptide hybrid constructs exhibiting increased MHC presentation-based immune cell activation useful for vaccines against SARS-CoV-2.

traducir

CONSTRUCTS COMPRISING SINGLE DOMAIN VHH ANTIBODIES AGAINST SARS-CoV-2

NºPublicación: WO2022140696A1 30/06/2022

Solicitante:

LUMEN BIOSCIENCE INC [US]

Resumen de: WO2022140696A1

The present disclosure relates to single domain antibodies ("VHHs") against SARS-CoV-2, as well as to polypeptides comprising one or more of such VHHs. The disclosure also relates to nucleic acids encoding such VHHs and polypeptides; to methods of preparing such VHHs and polypeptides; to host cells expressing or capable of expressing such VHHs or polypeptides; to compositions comprising such VHHs, polypeptides, nucleic acids or host cells; and to uses of such VHHs, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

traducir

BLOCKADE OF SARS-COV-2 INFECTION USING HYDROCARBON STAPLED PEPTIDES

NºPublicación: WO2022140591A1 30/06/2022

Solicitante:

UNIV CHICAGO [US]

Resumen de: WO2022140591A1

The disclosure is directed to methods of inhibiting coronavirus infection using a hydrocarbon stapled peptide which is a peptidomimetic of the human angiotensin-converting enzyme 2 (hACE2). The hydrocarbon stapled peptide binds to the receptor binding domain (RBD) of a coronavirus spike protein (S) and inhibits binding of the coronavirus to hACE2 expressed on the surface of host cells.

traducir

SEQUENCING MICROBIAL CELL-FREE NUCLEIC ACIDS TO DETECT INFLAMMATION, SECONDARY INFECTION, AND DISEASE SEVERITY

NºPublicación: WO2022140302A1 30/06/2022

Solicitante:

KARIUS INC [US]
UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]

Resumen de: WO2022140302A1

Described herein is a method of detecting secondary infection in a patient, particularly a patient with a primary infection that is a pneumonia, a COVID-19 infection, or a COVID-19 pneumonia. In some cases, the secondary infection is a secondary bacterial infection, e.g., secondary bacterial pneumonia. In some cases, the methods provided herein detect a hyper-inflammatory response or severity of disease, e.g., indicating a severe COVID-19 infection, or provide a risk of death from a disease (e.g., COVID-19). This disclosure also provides method of detecting a localized respiratory infection in a subject by quantifying microbial cell-free nucleic acids (e.g., mdfDNA) from plasma from the subject. In some cases, the subject is not bacteremic when plasma is collected from the subject. This disclosure also provides systems, such as nucleic acid-sequencing systems with increased reliability for detecting secondary infections, particularly in patients with culture-negative pneumonia.

traducir

METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE AND COMPOSITIONS FOR PRACTICING THE SAME, AND METHODS OF TREATING A SUBJECT FOR CHRONIC COVID-19

NºPublicación: WO2022140299A1 30/06/2022

Solicitante:

INCELLDX INC [US]

US_2021373034_A1

Resumen de: WO2022140299A1

Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.

traducir

SARS-COV-2 BINDING MOLECULES AND USES THEREOF

NºPublicación: WO2022139680A1 30/06/2022

Solicitante:

CHUGAI PHARMACEUTICAL CO LTD [JP]
AGENCY SCIENCE TECH & RES [SG]

Resumen de: WO2022139680A1

The present disclosure provides affinity matured SARS-CoV-2 antibodies with improved physiochemical property derived from a parent antibody that binds to the RBD domain of the SARS-CoV-2 spike protein. Said antibodies can also bind to SARS-CoV-2 protein muteins and have increased solubility. It further discloses a pharmaceutical composition comprising said antibodies and the use of said antibodies for treating and preventing SARS-CoV-2 infection, and for diagnosis of SARS-CoV-2.

traducir

A HERBAL NOSTRUM AGAINST HIV AND COVID-19

NºPublicación: WO2022136910A1 30/06/2022

Solicitante:

XAVIER JOSEPH ELIAS [IN]

Resumen de: WO2022136910A1

The invention relates to a nostrum against HIV and COVID-19. Roots of an Indian traditional medicinal plant are used against HIV (human immunodeficiency virus) and COVID-19 (Corona Virus Disease in 2019). Cures completely the diseases by said nostrum within days, and cures after affects and after effects of such virus disease. The nostrum is the roots of an Indian traditional medicinal plant named Plumbagin (Plumbago zeylanica and Plambago indica are more useful in the species for medicine).1 to 3 grams of grinded said root need to have divided as 2 or 3 times daily for 15 days against COVID-19 and 30 days for against AIDS (Acquired Immune Deficiency Syndrome) to cures. The quantity of the grinded said roots (dosage) may vary as per the age, weight and health of the patient.

traducir

WEARABLE COUGH SENSOR SYSTEM FOR PATIENT MONITORING

Nº publicación: WO2022136909A1 30/06/2022

Solicitante:

SHAFIABADI HASSANI NEDA [IR]

Resumen de: WO2022136909A1

This disclosure aims to introduce a low-cost portable monitoring system that can continuously measure the relevant metrics and detect cough for respiratory illnesses such as COVID-19 infection, including: Peripheral capillary oxygen saturation (SpO2), Cough occurrences, Heart rate, and Body temperature. As for the cough detection, the proposed design combines signals from an accelerometer and an audio sensor to automatically detect cough. Cost and accuracy are two competing factors in the development of wireless monitoring systems, with accurate products having a high cost affecting their potential for large scale usage. One distinguishing feature of our approach is minimizing costs by using simple hardware while maintaining high accuracy, partly by developing a powerful signal processing system based outside of the wearable part.

traducir

Página1 de 22 nextPage por página

punteroimgVolver